|
11 January 2017 |
Futura Medical plc
("Futura" or "the Company")
Director's Dealings
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan Freeman, a Non-Executive Director, transferred 35,803 shares of 0.2p each in the Company ("Ordinary Shares") from his personal holding into his Self-Invested Personal Pension account ("SIPP").
The transaction consisted of the sale by Jonathan Freeman and the immediate on market re-purchase by Mr. Freeman's SIPP of 35,803 Ordinary Shares at a price of 57.50p per share. There is no change to Mr. Freeman's beneficial holding of the Company's Ordinary Shares, which total 52,535 representing 0.04% of the Company's issued share capital.
Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.
For further information please contact:
|
Futura Medical plc |
|
James Barder, Chief Executive + 44 (0) 1483 685 670 |
|
N+1 Singer (Nominated Adviser and Broker) |
|
For media enquiries please contact: |
|
Buchanan |
|
Mark Court / Sophie Cowles /Stephanie Watson + 44 (0) 20 7466 5000 |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Jonathan Freeman |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Director/ PDMR |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Futura Medical plc |
||||
|
b) |
LEI |
21380053QLT46UNV2303 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 0.2p each GB0033278473 |
||||
|
b) |
Nature of the transaction |
Transfer of shares to SIPP through (i) sale by Jonathan Freeman and (ii) purchase by SIPP |
||||
|
c) |
Prices and volumes |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
Not applicable |
||||
|
e) |
Date of the transaction |
10 January 2017 |
||||
|
f) |
Place of the transaction |
(i) XLON (ii) XLON |
||||
This information is provided by RNS